Cardiac Risks Of Propoxyphene Raced Out Of Control As FDA Moved For Immediate Withdrawal

In deciding that the pain drug propoxyphene should come off the market, Center for Drug Evaluation and Research officials went from believing there was insufficient evidence of cardiac harm at therapeutic doses to concluding there was no way the risks of heart arrhythmia could be managed and mitigated.